NCT05383183招募中4 期
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 630
- 试验地点
- 4
- 主要终点
- Changes in ADAS-Cog scores
研究概览
简要总结
The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with donepezil alone.
详细描述
Aging population is a characteristic feature of demographic trends in developed countries. Hence, Alzheimer's disease is recognized as one of today's major healthcare challanges, and its significance will increase even more as the longevity of the population increases. Pre-clinical investigations have suggested that association between ChE-Is (cholinesterase inhibitors) and the cholinergic precursor choline alfoscerate enhances cholinergic neurotransmission more effectively than single compounds alone. This clinical trial is designed to assess if combination of the ChE-I donepezil with choline alfoscerate has a more favorable clinical profile than monotherapy with donepezil alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •<Screening Inclusion Criteria>
- •50 ≤ Age ≤ 85 at time of screening
- •Diagnosed as a probable Alzheimer Dementia patient according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria
- •10 ≤ K-MMSE-2 score ≤ 26 at time of screening
- •0.5 ≤ CDR score ≤ 2 at time of screening
- •Administration of donepezil 5 mg or 10 mg without dose change for at least 3 months at time of screening
- •Ability to walk or to move using a walking aid (i.e. senior walker, cane, or wheelchair)
- •Presence of a caregiver who regularly spends time with the patient and can accompany the patient to hospital visits
- •The caregiver must spend at least 8 hours per week with the patient
- •The caregiver should be able to supervise trial compliance and report subject status to the investigator
- •Sufficient visual acuity, hearing, language ability, motor function and comprehension, as judged by the investigator, to follow the examination procedure (auxiliary devices such as glasses and hearing aids are permitted)
- •Voluntarily decision to participate in this clinical trial from both the subject and the subject's legal representative
- •<Randomization Inclusion Criteria>
- •10 ≤ K-MMSE-2 score ≤ 26 at time of randomization
- •Compliance with donepezil ≥ 80% during run-in
排除标准
- •<Screening Exclusion Criteria>
- •Dementia due to other causes including:
- •Probable vascular dementia according to NINDS-AIREN criteria
- •Infection of the central nervous system (eg HIV, syphilis, etc.)
- •Head trauma
- •Creutzfeld-Jacob disease
- •Pixie's disease
- •Huntington's disease
- •Parkinson's disease
- •Drug addiction and/or Alcoholism
- •Patients with other major structural brain diseases (strategic cerebral infarction, subdural hematoma, traffic hydrocephalus, brain tumor) and/or evidence (CT or MRI results performed within the past 12 months or at screening) as the cause of dementia (provided that (Excluding lacunar cerebral infarction with a diameter of less than 1 cm in the area judged not to be related to cognitive function)
- •3 ≤ New Rating Scale for ARWMC (Age-Related White Matter Changes) score within 12 months of screening
- •Myocardial infarction, unstable angina pectoris, orthostatic hypotension or unexplained syncope within 12 months of screening, hospitalization for arrhythmia, or moderate to severe congestive heart failure (NYHA class III or IV), clinically Patients with significant structural heart disease (valvular disease, hypertrophic cardiomyopathy)
- •Serious mental disorders such as severe depression, schizophrenia, alcoholism, and drug dependence
- •History of malignant tumor within 5 years of screening. (However, enrollment is allowed if any of the following applies:)
- •More than 5 years since completion of treatment for tumor
- •Basal cell carcinoma, squamous cell carcinoma of the skin, or prostate cancer
- •Genetic problems such as galactose intolerance, lapp lactase deficiency or glucose galactose malabsorption
- •Gastrointestinal diseases (inflammatory bowel disease, etc.) that may affect the absorption of clinical investigational drugs
- •Administration of other dementia treatments (galantamine, rivastigmine, memantine) than donepezil within 3 months of screening
- •Administration of brain function improving drugs (citicoline, oxiracetam, piracetam, choline alfoscerate, Nicergoline, Nimodipine, ginko-biloba, acetyl-l carnitine, etc.) within 1 month of screening
- •Administration of dementia treatments, brain function improving agents, central nervous system stimulants, anticholinergics, tricyclic antidepressants, classic antipsychotics, and hypnotics (excluding short-acting hypnotics) other than experimental drugs during trial period
- •Administration of atypical antipsychotics, anxiolytics, antidepressants (except tricyclic antidepressants), thyroid hormones, short-acting hypnotics, hormone replacement therapy, vitamin E, vitamin B12 supplements, antiparkinsonian drugs, and cholinergic drugs during trial period (However, enrollment is allowed if all of the following apply:)
- •Administration without any changes in dosage within 2 months of randomization
- •Administration without any changes in dosage during trial period
- •except for PRN drugs
- •Hypersensitivity to clinical investigational drugs (choline alfoscerate, donepezil), its components, or piperidine derivatives
- •Possibility of dementia due to abnormalities in vitamin B12, folic acid, and thyroid stimulating hormone (TSH) levels
- •Abnormalities in blood tests at screening:
- •Liver dysfunction: AST or ALT ≥ 3 times the upper limit of normal range
- •Renal dysfunction: Creatinine clearance* < 25 mL/min/1.73 m2
- •*MDRD Formula Creatinine clearance (mL/min/1.73m2)= 175 × {serum Creatinine (mg/dL)}- 1.154 × (Age)-0.203 × 0.742 (for female only)
- •Uncontrolled hypertension (SBP>180 mmHg)
- •Pregnancy and lactation
- •In case of a woman, a patient who does not fall under any of the following:
- •Menopause for at least 2 years at time of screening
- •Contraceptive through surgical methods
- •Deemed inappropriate for enrollment by the investigator for other reasons <Randomization Exclusion Criteria>
- •Abnormalities in blood tests at time of randomization
- •Liver dysfunction: AST or ALT ≥ 3 times the upper limit of normal range
- •Renal dysfunction: Creatinine clearance* < 25 mL/min/1.73 m2 *MDRD Formula Creatinine clearance (mL/min/1.73m2)= 175 × {serum Creatinine (mg/dL)}- 1.154 × (Age)-0.203 × 0.742 (for female only) 2) Uncontrolled hypertension (SBP>180 mmHg) at the time of randomization 3) Administration of other investigational drugs within the past 3 months from the time of randomization 4) Deemed inappropriate for enrollment by the investigator for other reasons
研究组 & 干预措施
Choline Alfoscerate 1,200mg + Donepezil 5mg or 10mg
Experimental
Oral administration of choline alfoscerate 400mg TID, donepezil QD (evening) for 48 weeks, no dosage change during trial period
干预措施: Choline Alfoscerate 400mg (Drug)
Placebo + Donepezil 5mg or 10mg
Placebo Comparator
Oral administration of placebo TID, donepezil QD (evening) for 48 weeks, no dosage change during trial period
干预措施: Placebo (Drug)
结局指标
主要结局
Changes in ADAS-Cog scores
时间窗: 48 weeks from baseline
ADAS-cog change at 12 and 24 weeks from baseline Changes in ADAS-Cog scores at 48 weeks from baseline
次要结局
- Changes in K-IADL scores(12, 24, and 48 weeks from baseline)
- Changes in CDR-SB scores(12, 24, and 48 weeks from baseline)
- Changes in ADAS-Cog scores(Time Frame: 12, 24 weeks from baseline)
- Changes in K-MMSE-2 scores(12, 24, and 48 weeks from baseline)
- Changes in ADCOMS scores(12, 24, and 48 weeks from baseline)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth HormoneElderlyNCT00533065Ludwig Boltzmann Gesellschaft80
Unknown
4 期
CALM-ADAlzheimer's DiseaseNCT00142324Institute of Psychiatry, London190
已完成
4 期
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular DiseaseDementia Associated With Cerebrovascular DiseaseNCT02660983Eisai Co., Ltd.302
已完成
2 期
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down SyndromeDown SyndromeNCT00570128Eisai Inc.129
已完成
3 期
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's DiseaseAlzheimer's Type DementiaNCT01404169Eisai Limited260